Engflag

Diclon 50

Quick links to important sections

Diclon 50

Diclon 50_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclon 50

Quick Facts

Property Description
Active Ingredient Diclofenac Sodium
Form Oral Tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic Drug (Phenylacetic Acid Derivative)
General Purpose Symptomatic relief of pain, inflammation, and fever

What Type of Medicine is Diclon 50?

Diclon 50 is a single-ingredient medicinal product whose active component is Diclofenac Sodium, classified pharmacologically as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification places it within a common group of synthetic drugs recognized for their ability to manage pain and inflammation across the body. The core substance, Diclofenac Sodium, is a powerful systemic agent and a synthetic Phenylacetic Acid derivative.

Composition, Form, and Origin

Diclon 50 is presented as an oral solid preparation, specifically a tablet, which is administered through the oral route to ensure systemic absorption. The designation "50" explicitly indicates the strength of the unit dose, referring to the quantity of Diclofenac Sodium contained within the tablet. Unlike naturally derived remedies, the active ingredient is a synthetic drug, meaning it is manufactured to consistently inhibit the chemical pathways responsible for discomfort and swelling. This preparation uses various solid excipients (binders, fillers) to form the tablet matrix, ensuring stable delivery of the drug to the gastrointestinal tract.

General Purpose: What Does Diclon 50 Do?

The general purpose of Diclon 50 is to provide integrated symptomatic relief by targeting the body's inflammatory and pain response mechanisms. Through its action as a Cyclooxygenase (COX) Inhibitor, the medicine essentially interrupts the processes that generate pain signals and cause local swelling, heat, and redness. This results in three distinct benefits: a pronounced anti-inflammatory action, a significant analgesic effect (pain relief), and an antipyretic action (fever reduction), supporting the overall reduction of physical discomfort stemming from various conditions.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information
  2. WHO Model Lists of Essential Medicines

What side effects are possible with Diclon 50?

Possible Side Effects and Safety Information

The safety profile of Diclon 50 (Diclofenac Sodium) is structured by official regulatory bodies, classifying adverse reactions by frequency and affected physiological systems. This medicine belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, which is associated with certain established risks documented in regulatory labeling.

Officially Documented Adverse Reactions

The most frequently reported adverse reactions, classified as common in clinical trials (1%–10% incidence), often involve the Gastrointestinal System and Nervous System. These may include abdominal pain, indigestion, diarrhea, nausea, headache, dizziness, and fluid retention. Reactions affecting the Hepatobiliary System, such as elevated liver enzymes, are also classified as common [DailyMed].

Serious Safety Considerations

Official labeling highlights the potential for Serious Cardiovascular Thrombotic Events, including myocardial infarction and stroke, which can be fatal. This risk may increase with the duration of use and higher doses. Similarly, the drug is associated with serious, potentially fatal, Gastrointestinal Events, such as bleeding, ulceration, or perforation of the stomach or intestines, which can occur at any time during treatment [FDA].

Safety Constraints and Special Populations

Safety notes specify that use must be avoided in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery. Caution is officially documented for the elderly, as they face a greater risk for serious gastrointestinal events. Furthermore, the label advises avoiding use in the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus [DailyMed].

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected acute overdose of Diclon 50 (Diclofenac Sodium) necessitates immediate medical attention. This mandate is strictly based on official government regulatory labeling to address the potential for severe, life-threatening toxicity.

Documented Clinical Manifestations

Officially documented signs of overdose often involve Gastrointestinal (GI) and Central Nervous System (CNS) disturbances. GI symptoms may include nausea, vomiting, epigastric pain, diarrhea, and generalized stomach pain. CNS effects typically include drowsiness, lethargy, headache, dizziness, and sometimes tinnitus or confusion.

Severe Outcomes and Emergency Protocol

Regulators list severe outcomes such as acute renal failure, gastrointestinal bleeding, perforation, and serious neurological events like seizures and coma. In these circumstances, the official instruction is to seek medical help right away or immediately contact a poison control center. The labeling specifically notes that the risk of serious GI events is higher in the elderly patient population.

Management and Monitoring

No specific antidote is known for Diclofenac overdose. Therefore, treatment is defined as symptomatic and supportive, which may include procedural steps like gastric decontamination or administration of activated charcoal to reduce drug absorption. Continuous hospital monitoring is required for symptomatic patients or large ingestions, often for a minimum of four hours to observe for delayed toxicity.

Therapeutic Uses of Diclon 50

What Diclon 50 Treats: Main Uses and Benefits

Diclon 50 is used for short-term symptomatic relief and is part of the supportive management for various conditions presenting with distressing symptoms and physical discomfort. It is typically applied when symptoms create noticeable interference with daily comfort and require temporary assistance. Diclofenac is generally used to relieve mild to moderate pain and helps address symptoms related to inflammatory or irritative states.

Key Areas of Symptom Management

This medicine is commonly used across conditions presenting with acute episodes or those characterized by recurrent or fluctuating manifestations. It is applied in situations involving acute discomfort from musculoskeletal strain, temporary pain following minor procedures, or symptom clusters that may become intense or disruptive. The medication assists with managing symptoms that interfere with daily functioning, particularly during periods of heightened physiological stress.

The medication may assist with managing symptoms related to pain and swelling.

Quick Fact: Addresses symptoms of Acute Discomfort The treatment is considered relevant when supportive symptom management is appropriate. This supportive role contributes to easing the overall symptom load, helping patients cope more steadily during difficult episodes. Diclon 50 supports general well-being by providing supportive relief when symptoms become more noticeable.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Diclon 50

This information is based strictly on contraindications and restrictions documented in official government regulatory labels (e.g., FDA, EMA).

Absolute Contraindications (Must Not Use)

Condition/Population Restriction Basis
Allergy/Hypersensitivity Known allergy to Diclofenac or a history of asthma, hives, or allergic reactions after taking Aspirin or other NSAIDs.
Cardiovascular Disease Established Congestive Heart Failure (NYHA II–IV), Ischaemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease.
Gastrointestinal Active stomach or intestinal ulceration, bleeding, or perforation.
Surgical Status Perioperative pain treatment in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy The last trimester (from approximately 30 weeks gestation) due to risk to the fetus.

Restricted or Conditional Use

Population/Condition Eligibility Status
Children/Adolescents Not recommended or not suitable for those under 14–18 years of age, depending on the specific product label.
High-Risk Factors Use requires careful consideration and the lowest effective dose in patients with significant risk factors for cardiovascular events (e.g., hypertension, diabetes) or GI events.
Organ Impairment Caution and potential dose adjustment are necessary for patients with mild to moderate hepatic or renal impairment.

Official labeling defines eligibility based on excluding populations with specific high-risk conditions or clinical states where use is prohibited. Eligibility is otherwise established for adults who do not possess these contraindications. Individuals falling into restricted categories may only be eligible after thorough medical assessment and supervised use, generally prioritizing short-term, low-dose treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diclon 50 (Diclofenac Sodium) interactions are classified by regulatory bodies based on the risk of additive effects or alterations in systemic drug exposure.

Pharmacodynamic and Contraindicated Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin, is generally not recommended due to a significant increase in the risk of serious gastrointestinal adverse events, such as bleeding and ulceration. The medicine is contraindicated for use in the peri-operative setting of pain management for Coronary Artery Bypass Graft (CABG) surgery.

Combining Diclon 50 with Anticoagulants (like Warfarin) or Antiplatelet Agents increases the pharmacodynamic risk of serious bleeding. The co-administration of alcohol is also associated with an increased risk of severe gastrointestinal mucosal irritation and bleeding.

Pharmacokinetic and Efficacy Alterations

Diclon 50 is a substrate primarily metabolized by the CYP2C9 enzyme. When taken with inhibitors of this pathway, such as Voriconazole, regulatory documents confirm a pharmacokinetic interaction leading to increased systemic exposure of Diclofenac. Conversely, the medicine may elevate the plasma concentrations of co-administered drugs like Lithium, Methotrexate, and Digoxin by impairing their renal clearance.

Furthermore, Diclon 50 may diminish the therapeutic effect of ACE Inhibitors, ARBs, and Diuretics. This combination carries a specific regulatory caution for the elderly, volume depleted, or renal impairment populations due to the potential for deterioration of renal function.

Mechanism of Action

The drug's action is defined by the modulation of biochemical signaling pathways through enzyme inhibition. The mechanism operates across distinct domains, engaging enzymes and molecular cascades to establish its physiological consequences.

Enzyme Inhibition and Mediator Suppression

The core of the mechanism involves the inhibition of the Cyclooxygenase (COX) enzyme system, showing a preferential affinity for the inducible COX-2 form. The drug acts as a competitive blocker, preventing the natural substrate, Arachidonic Acid, from binding to the enzyme's active site. This action directly suppresses the production of lipid mediators, most notably Prostaglandin E2 (PGE2, resulting in the restriction of chemical signals that contribute to physiological activity.

Causal Cascade to Physiological Adjustment

The reduction in PGE2 and related Prostaglandins initiates a causal cascade that modifies physiological parameters. In peripheral tissues, diminished PGE2 production lowers the sensitization of pain-sensing neurons and modulates local vascular permeability. Centrally, the mechanism operates in the brain's hypothalamus to reset the body's core temperature set point.

Mechanistic Constraint and Scope Limit

The mechanism is constrained by its inherent partial non-selectivity, which includes the inhibition of the constitutive COX-1 enzyme, a necessary biological trade-off. COX-1 inhibition restricts the production of protective Prostaglandins that regulate baseline physiological processes, such as the maintenance of the gastric mucosa, illustrating the functional consequences of the drug's action across both COX enzyme subtypes.

Dosage and Administration Information

How to Use Diclon 50

The administration of Diclon 50 (Diclofenac Sodium 50 mg oral tablet) involves following specific guidelines regarding the route, dosing schedule, and physical handling of the tablet. This medicine is typically used at the lowest effective dose for the shortest duration possible, with the necessity for continued use being periodically re-evaluated.

Official Administration Guidelines

Instruction Entity General Principle
Route of Administration The tablets are intended for oral use only.
Dosing Schedule Dosing for chronic conditions like osteoarthritis typically ranges from 100 mg to 150 mg per day in divided doses, meaning a 50 mg tablet is generally taken two or three times daily. The total daily dose should generally not exceed 150 mg for continuous treatment.
Tablet Handling Tablets, particularly the delayed-release form, must be swallowed whole with liquid and must not be crushed, split, or chewed, as this compromises the special coating required for proper absorption.
Timing with Meals Diclofenac delayed-release tablets can be taken with or without food; however, administration with food may delay the onset of pain relief.
Age-Group Rules The 50 mg strength is generally not recommended for use in children and adolescents under 14 years of age. Older adults should begin therapy using the lowest effective dose.

Procedural Summary

The standardized use protocol requires that the medicine be taken as a whole, intact tablet, following a divided daily dosing pattern to maintain the necessary dose levels. The maximum daily dose limit enforces a controlled administration to standardize the regimen across different conditions. The overall protocol follows the principle of using the minimum amount necessary for the minimum time required.

Recent Clinical Evidence

Overview of Studies for Diclon 50

Evidence for Use in Chronic Inflammatory Conditions

The research that exists exploring how symptoms change over time in these conditions characterized by fluctuating or episodic manifestations primarily consists of Randomized Controlled Trials (RCTs). These studies were studied for patient populations including Adults and Older Adults with established diagnoses of joint conditions. Researchers examined outcomes related to physical discomfort (pain intensity) and outcomes reflecting daily functioning or activity level, using tools like the WOMAC function subscale to monitor how symptoms are measured. Follow-up durations in this evidence base ranged from short-term periods of a few weeks up to intermediate periods of 3 to 12 months. The evidence is limited to outcomes related to physical discomfort and does not examine outcomes related to disease progression or structural changes in the joints.

Evidence for Use in Acute Musculoskeletal Pain

The research exploring short-term symptom changes in acute scenarios was evaluated in well-structured Randomized Controlled Trials (RCTs) during studies conducted during periods of increased symptom activity. Studies monitored outcomes describing episodic or acute changes, specifically focusing on rapid changes in pain scores. The evidence monitored immediate, short-term symptom patterns. Follow-up durations were limited, and there is limited information for long-term outcomes associated with the use of Diclon 50 extending beyond the typical acute course of one to two weeks for these indications. The research results apply only to the populations studied.

What the Research Still Classifies as Uncertain

The existing evidence highlights what is known—and what is still uncertain. A primary gap is that the research is predominantly focused on demonstrating changes in symptoms—specifically pain, inflammation, and function. Research does not provide data to predict whether an individual will respond similarly to the group patterns, and findings do not address whether the medicine alters the underlying progression of the disease (e.g., joint damage in arthritis). Long-term effects are not fully established, particularly for use extending over several years, and data for certain groups remain insufficient.

How should Diclon 50 be stored and disposed of?

How to Store and Dispose of Diclon 50: Official Regulatory Requirements

Storage and disposal instructions for Diclon 50 (Diclofenac Sodium tablets) are defined by government-approved labeling to ensure product integrity and safety.

Storage Conditions

Requirement Detail
Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F).
Protection The medication must be protected from moisture.
Child Safety Keep the product out of the reach of children.

Disposal Instructions

Unused or expired Diclon 50 should be discarded using a drug take-back program or official collection site when possible. If a take-back program is unavailable, the tablets may be prepared for household trash by mixing them with an undesirable substance, such as dirt or used coffee grounds, and sealing the mixture in a plastic bag before disposal. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diclon 50 found in:

A-Z Index: